A month after acquiring obesity biotech Metsera, Pfizer's expanding in the weight loss drug market after signing a licensing agreement for a weight loss pill.
Yao Pharma's deal with the US pharmaceutical giant underscores China's growing role in global biotech licensing US ...
Obesity China's sixth leading risk factor in disability, death Number of overweight, obese to increase to 65% by 2030 Weight-loss drugs too expensive, doctors say Generics could bring price pressure, ...
The deal will help Pfizer beef up and diversify its obesity drug pipeline following its $10 billion acquisition of obesity ...
A recently approved antibody drug from Regeneron Pharmaceuticals eradicates residual traces of multiple myeloma after initial ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Some patient populations may be at higher risk for lean ...
AFTER AMERICA, China is the world’s largest developer of new medicines. Its companies ran nearly a third of the planet’s clinical trials last year. That is up from just 5% a decade before (see chart 1 ...
What Are GLP-1 Drugs? Obesity Drug Leaders Novo and Eli Lilly Look Overvalued Obesity Drug Candidates Must Stand Out Startups Emerge in the Obesity Treatment Landscape Improve Your Business Novo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback